Pharma Fast 50 Report 2021
We are extremely excited to announce that we have been named in this year’s Pharma Fast 50, the annual ranking of the fastest-growing privately-owned pharmaceutical and pharmaceutical service companies in the UK.
The Pharma Fast 50 annual report is compiled by Alantra, the global investment bank, and is presented by the PharmaTimes, the UK’s leading pharmaceutical magazine. The report selects UK businesses within the pharmaceutical industry, which have shown rapid revenue growth over the past two years.
Alantra’s annual ranking showcases the UK’s fastest-growing, privately-owned pharma and pharma service companies, highlighting their success. These are dynamic and innovative businesses that continue to deliver remarkable growth. The report includes an analysis of businesses found across various sectors, touching on every element – from early-stage research right through to ensuring vital medicines continue to flow across borders.
Companies ranked in the Alantra Pharma Fast 50 report show great commitment and passion to their business’s potential to successfully grow, innovate and achieve. The hard work, determination, and ambition of these companies stand testament to the great achievements and success of the UK’s pharmaceutical industry, particularly in a year like no other.
In 2020 the world turned upside-down, and the pharma sector was no exception. As COVID-19 spread globally and lockdowns took effect, the pharmaceutical industry, like many industries, had to adapt quickly, responding with a surge of adaptability, resilience and innovation. The way in which the pharmaceutical industry has confronted the difficulties of the past 12 months has been inspiring, and the companies selected in this report have shown huge motivation and collaboration to continue to succeed and grow despite the added strain caused by the pandemic. The Alantra Pharma Fast 50 shines a light on the incredible work of many of the industry’s most innovative growing businesses.
The 2021 report marks our second appearance in the Alantra Pharma Fast 50 ranking in three years. Our 3D medical animation services and ability to visually convey scientific concepts and products have been credited in Alantra’s report as we “continue to wow clients and end consumers”. As complex new drug modalities become even more difficult to articulate, the need for animations and visual storytelling becomes greater than ever.
Our CEO and Medical Director, Ben Ramsbottom, explains… “Every product needs an animation at some stage, but the complexity makes it even more important to think about how you tell your story, moreover, the number of companies that have stories to tell continues to proliferate, particularly in the buoyant biotech sector of North America.”
As a company, we continue to innovate in this space. Our capabilities push far beyond animation as we further explore the realms of augmented and virtual reality, to heighten our scientific storytelling to new levels. During the Covid-19 pandemic, we have produced important animations for vaccine developers to accurately demonstrate their work in an engaging format. The visual assets we have created during this pandemic have helped many drug developers communicate core scientific messages and findings to a variety of stakeholders at a time where conferences and face-to-face meetings are non-existent.
Ben Ramsbottom, Random42 CEO and Medical Director, commented on this fantastic achievement:
See Alantra’s Pharma Fast 50 for the full article.